New hope for kids with severe food allergies

Dr Linda Calabresi

writer

Dr Linda Calabresi

GP; Medical Editor, Healthed

Dr Linda Calabresi

One of the new class of biologics may have a pivotal role in desensitising children with severe food allergies, US researchers say.

That was the conclusion after their placebo-controlled study showed that a preliminary short course of the monoclonal antibody, omalizumab (Xolair) improved the safety and efficacy of oral immunotherapy in children with multiple severe Ig-E mediated food allergies.

Admittedly the study was small, involving only 48 children aged 4-15 years, and only looked at children with Ig-E mediated allergies to multiple foods but the implications, the study authors say are important.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Kate Walsh

Dr Kate Walsh

Endometriosis Cases – Practical Guide

Prof Finlay Macrae AO

Prof Finlay Macrae AO

Familial Colorectal Cancer

Prof Richard Harvey

Prof Richard Harvey

Recurrent Nasal Polyps Management – When to Refer

Prof Terence O'Brien

Prof Terence O'Brien

SUDEP – What is it and How to Reduce the Risk

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

We invite you to join the upcoming Healthed webcast where we will focus on working through the popular management myths and misperceptions in general practice with the aim of improving patient outcomes and quality of life.

Tuesday 19th August, 7pm AEST